|
THE JENEX CORPORATION REVISES INCENTIVE STOCK OPTIONS
September 12, 2007
News Release
For Immediate Release
THE JENEX CORPORATION REVISES INCENTIVE STOCK OPTIONS
THE JENEX CORPORATION REPLACES PREVIOUSLY ANNOUNCED INCENTIVE STOCK OPTIONS
Burlington, Ontario – The Jenex Corporation (“Jenex” or the “Corporation”) TSX Venture Exchange: JEN, Frankfurt: JNX) announced today that the corporation has agreed to grant 2,750,000 incentive stock options to Directors, Officers, Employees and Consultants of the corporation, exercisable at a price of thirty-five cents ($0.35) per share. Whereas, 2,400,000 incentive stock options are for a three year term ending September 12, 2010 and 350,000 incentive stock options are for a two year term ending September 12, 2009. Option specifics are governed by the TSX-V requirements. The transaction is subject to customary TSX Venture Exchange approval and options shall be subject to a four month hold period. The granting of these incentive stock options replaces the incentive stock options previously announced in a press release dated May 25, 2007.
About The Jenex Corporation
The Jenex Corporation owns a patented Thermal Therapy technology. The first device developed from this technology is the Therapik® product, for relief of pain and itch caused by insect stings and bites. Therapik® has been approved as a Class II medical device in Canada (TPD) and the United States (FDA), and has received CE approval in Europe. The second device, interceptCS is the first product clinically proven and approved (TPD) to prevent cold sores . interceptCS is available exclusively in Canada at Shoppers Drug Mart/Pharmaprix. More information about the Corporation can be found at www.jenexcorp.com and www.interceptCS.com.
“Prevention is the Solution”
The TSX Venture Exchange Inc. has not reviewed and does not accept responsibility
for the accuracy or the contents of this press release.
Direct Inquiries to:
The Jenex Corporation
207 - 940 Sheldon Court
Burlington, Ontario L7L 5K6
Michael A. Jenkins
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
Website: www.jenexcorp.com
|
